[{"id":"c1b27e69-5cb6-4c7f-a2c7-df42fb2ed239","acronym":"CYTOK-AZA","url":"https://clinicaltrials.gov/study/NCT06439199","created_at":"2024-06-08T04:34:20.475Z","updated_at":"2024-07-02T16:34:59.405Z","phase":"","brief_title":"Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy","source_id_and_acronym":"NCT06439199 - CYTOK-AZA","lead_sponsor":"Nantes University Hospital","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/15/2024","start_date":" 06/15/2024","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-03"},{"id":"f8c1fb30-1e93-4d1d-b601-a40aa00e7c6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01995578","created_at":"2021-01-18T09:06:13.620Z","updated_at":"2024-07-02T16:35:02.011Z","phase":"Phase 2","brief_title":"Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse","source_id_and_acronym":"NCT01995578","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 09/27/2023","primary_completion_date":" 09/27/2023","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2024-05-22"},{"id":"2d6f093a-de07-4209-b284-2545149189bc","acronym":"BRE-04","url":"https://clinicaltrials.gov/study/NCT04891068","created_at":"2021-05-18T12:02:05.434Z","updated_at":"2024-07-02T16:35:02.524Z","phase":"Phase 2","brief_title":"BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer","source_id_and_acronym":"NCT04891068 - BRE-04","lead_sponsor":"University of Illinois at Chicago","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/10/2022","start_date":" 01/10/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-20"},{"id":"e6e36ef9-1a28-4271-9c2d-5395fb082dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT06390306","created_at":"2024-04-30T19:56:36.690Z","updated_at":"2024-07-02T16:35:06.686Z","phase":"","brief_title":"The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP","source_id_and_acronym":"NCT06390306","lead_sponsor":"Peking University People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • Nailike (olverembatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"26556d3b-e333-41d1-a129-50ec08ae32ca","acronym":"AALL15P1","url":"https://clinicaltrials.gov/study/NCT02828358","created_at":"2021-07-12T20:53:08.460Z","updated_at":"2024-07-02T16:35:13.043Z","phase":"Phase 2","brief_title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","source_id_and_acronym":"NCT02828358 - AALL15P1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"cb11cd54-0bac-4f20-bf14-95c5e18524bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187703","created_at":"2022-04-24T09:01:41.679Z","updated_at":"2024-07-02T16:35:15.464Z","phase":"Phase 1","brief_title":"5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies","source_id_and_acronym":"NCT04187703","lead_sponsor":"Benjamin Tomlinson","biomarkers":" ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"},{"id":"a9c92323-37b4-4ef5-81cf-0e514f050b3f","acronym":"AGIR","url":"https://clinicaltrials.gov/study/NCT03666559","created_at":"2021-01-18T17:59:24.102Z","updated_at":"2024-07-02T16:35:16.956Z","phase":"Phase 2","brief_title":"Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation","source_id_and_acronym":"NCT03666559 - AGIR","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 02/23/2023","primary_completion_date":" 02/23/2023","study_txt":" Completion: 03/23/2024","study_completion_date":" 03/23/2024","last_update_posted":"2024-02-29"},{"id":"cb1eef0a-e163-46d8-8f49-52a6658d6c5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06256627","created_at":"2024-02-13T20:25:59.985Z","updated_at":"2024-07-02T16:35:19.538Z","phase":"","brief_title":"The Maintenance Treatment of \"ITIVA\" in AML Patients","source_id_and_acronym":"NCT06256627","lead_sponsor":"Henan Cancer Hospital","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • thalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-02-13"},{"id":"894cf8cb-0456-4299-b86d-2ea4d23be60a","acronym":"BMP-MDS","url":"https://clinicaltrials.gov/study/NCT06175923","created_at":"2023-12-20T06:19:40.931Z","updated_at":"2024-07-02T16:35:22.504Z","phase":"","brief_title":"Role of BMP Pathway in MDS Progression","source_id_and_acronym":"NCT06175923 - BMP-MDS","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" BMP2 • BMP4","pipe":"","alterations":" ","tags":["BMP2 • BMP4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/27/2024","start_date":" 01/27/2024","primary_txt":" Primary completion: 01/27/2029","primary_completion_date":" 01/27/2029","study_txt":" Completion: 01/27/2034","study_completion_date":" 01/27/2034","last_update_posted":"2024-01-23"},{"id":"4df095d5-85b3-400e-86eb-3ef2e22e4f1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03513484","created_at":"2021-01-18T17:17:32.073Z","updated_at":"2024-07-02T16:35:25.364Z","phase":"Phase 1","brief_title":"Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03513484","lead_sponsor":"Northwestern University","biomarkers":" FLT3 • KMT2A • CD34 • HOXA9 • FGF2","pipe":" | ","alterations":" HOXA9 overexpression","tags":["FLT3 • KMT2A • CD34 • HOXA9 • FGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HOXA9 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-12-22"},{"id":"65d7fa77-c42c-49f2-a8cf-35bffe7893bd","acronym":"MC2TCR","url":"https://clinicaltrials.gov/study/NCT04729543","created_at":"2021-01-28T12:53:16.382Z","updated_at":"2024-07-02T16:35:27.282Z","phase":"Phase 1/2","brief_title":"MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer","source_id_and_acronym":"NCT04729543 - MC2TCR","lead_sponsor":"Erasmus Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 12/20/2024","primary_completion_date":" 12/20/2024","study_txt":" Completion: 10/20/2027","study_completion_date":" 10/20/2027","last_update_posted":"2023-12-04"},{"id":"a25a7657-8064-40e7-806c-f6d355167a9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042531","created_at":"2021-09-13T14:55:55.634Z","updated_at":"2024-07-02T16:36:11.575Z","phase":"","brief_title":"Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia","source_id_and_acronym":"NCT05042531","lead_sponsor":"LanZhou University","biomarkers":" TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A","pipe":"","alterations":" ","tags":["TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/13/2021","start_date":" 11/13/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-04-25"},{"id":"11f21814-8048-4c09-a674-b93785eb65ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02178072","created_at":"2021-01-18T10:09:20.164Z","updated_at":"2024-07-02T16:36:17.134Z","phase":"Phase 1","brief_title":"Window Trial 5-aza in HNSCC, T-tare","source_id_and_acronym":"NCT02178072","lead_sponsor":"Yale University","biomarkers":" CASP3 • CDKN1A","pipe":"","alterations":" ","tags":["CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 02/19/2015","start_date":" 02/19/2015","primary_txt":" Primary completion: 10/23/2019","primary_completion_date":" 10/23/2019","study_txt":" Completion: 10/23/2019","study_completion_date":" 10/23/2019","last_update_posted":"2022-02-15"},{"id":"16804637-9fe5-4282-a88d-f5ffa656bdf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05123352","created_at":"2021-11-17T12:53:30.453Z","updated_at":"2024-07-02T16:36:20.639Z","phase":"","brief_title":"Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies","source_id_and_acronym":"NCT05123352","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2021-11-17"},{"id":"39f77630-d628-4900-bf4e-fdf365b2431e","acronym":"RELAZA2","url":"https://clinicaltrials.gov/study/NCT01462578","created_at":"2021-01-18T06:05:02.688Z","updated_at":"2024-07-02T16:36:20.773Z","phase":"Phase 2","brief_title":"Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)","source_id_and_acronym":"NCT01462578 - RELAZA2","lead_sponsor":"Technische Universität Dresden","biomarkers":" KIT • NPM1 • CD34","pipe":"","alterations":" ","tags":["KIT • NPM1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-11-15"},{"id":"544d4614-f791-4bd3-b59b-92ae1a8a0f06","acronym":"","url":"https://clinicaltrials.gov/study/NCT02497404","created_at":"2021-01-18T12:02:35.681Z","updated_at":"2024-07-02T16:36:24.176Z","phase":"Phase 2","brief_title":"Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR","source_id_and_acronym":"NCT02497404","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • DNMT3A • RUNX1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • ZRSR2","pipe":" | ","alterations":" DNMT3A mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • U2AF1 mutation","tags":["FLT3 • DNMT3A • RUNX1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNMT3A mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Campath (alemtuzumab) • melphalan • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/13/2015","start_date":" 02/13/2015","primary_txt":" Primary completion: 06/17/2020","primary_completion_date":" 06/17/2020","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2021-09-22"},{"id":"d2faf2b9-af61-4fac-b07d-98cf26f0e769","acronym":"","url":"https://clinicaltrials.gov/study/NCT03397173","created_at":"2021-01-18T16:45:54.032Z","updated_at":"2024-07-02T16:36:26.502Z","phase":"Phase 2","brief_title":"TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid","source_id_and_acronym":"NCT03397173","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" FLT3 • TET2","pipe":" | ","alterations":" TET2 mutation","tags":["FLT3 • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 01/03/2021","primary_completion_date":" 01/03/2021","study_txt":" Completion: 01/21/2021","study_completion_date":" 01/21/2021","last_update_posted":"2021-08-11"},{"id":"8c3f0361-796d-4885-a0b8-e4b7e531993d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01861002","created_at":"2021-01-18T08:19:13.965Z","updated_at":"2024-07-02T16:36:29.375Z","phase":"Phase 1","brief_title":"A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML","source_id_and_acronym":"NCT01861002","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" BLM","pipe":"","alterations":" ","tags":["BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/22/2013","start_date":" 05/22/2013","primary_txt":" Primary completion: 07/28/2014","primary_completion_date":" 07/28/2014","study_txt":" Completion: 07/28/2014","study_completion_date":" 07/28/2014","last_update_posted":"2021-06-09"},{"id":"fc61429b-02e4-47dd-8e39-d891112660b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01839240","created_at":"2021-01-18T08:11:28.225Z","updated_at":"2024-07-02T16:36:45.010Z","phase":"Phase 1","brief_title":"Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT01839240","lead_sponsor":"University of Chicago","biomarkers":" DCK","pipe":" | ","alterations":" TOP2A expression","tags":["DCK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TOP2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/06/2012","start_date":" 06/06/2012","primary_txt":" Primary completion: 08/16/2019","primary_completion_date":" 08/16/2019","study_txt":" Completion: 08/16/2019","study_completion_date":" 08/16/2019","last_update_posted":"2020-05-15"},{"id":"28f437aa-8eaa-459d-8b43-29719db9a821","acronym":"","url":"https://clinicaltrials.gov/study/NCT02450877","created_at":"2021-01-18T11:45:03.113Z","updated_at":"2024-07-02T16:36:52.205Z","phase":"Phase 2","brief_title":"A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.","source_id_and_acronym":"NCT02450877","lead_sponsor":"Celgene","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • RUNX1T1","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 10/10/2018","primary_completion_date":" 10/10/2018","study_txt":" Completion: 10/08/2019","study_completion_date":" 10/08/2019","last_update_posted":"2019-12-20"},{"id":"bef2d1de-fe6b-4a1a-afd6-2e7ba2b0ef48","acronym":"","url":"https://clinicaltrials.gov/study/NCT01281124","created_at":"2021-05-21T18:52:45.139Z","updated_at":"2024-07-02T16:36:55.287Z","phase":"Phase 2","brief_title":"Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01281124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MIR29A","pipe":"","alterations":" ","tags":["MIR29A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 01/12/2011","start_date":" 01/12/2011","primary_txt":" Primary completion: 04/15/2011","primary_completion_date":" 04/15/2011","study_txt":" Completion: 09/12/2012","study_completion_date":" 09/12/2012","last_update_posted":"2019-09-24"},{"id":"d582e599-215d-4eb6-8b2c-a2836eb99b24","acronym":"","url":"https://clinicaltrials.gov/study/NCT02447666","created_at":"2021-01-18T11:43:49.376Z","updated_at":"2024-07-02T16:36:58.220Z","phase":"Phase 2","brief_title":"Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)","source_id_and_acronym":"NCT02447666","lead_sponsor":"Celgene","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/15/2015","start_date":" 09/15/2015","primary_txt":" Primary completion: 02/28/2018","primary_completion_date":" 02/28/2018","study_txt":" Completion: 05/24/2019","study_completion_date":" 05/24/2019","last_update_posted":"2019-07-11"},{"id":"4068bbcf-6bb9-499e-9e7f-27b67acb6de7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00439673","created_at":"2021-01-18T01:33:12.069Z","updated_at":"2024-07-02T16:37:08.160Z","phase":"Phase 2","brief_title":"PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS","source_id_and_acronym":"NCT00439673","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 05/01/2007","start_date":" 05/01/2007","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 07/01/2010","study_completion_date":" 07/01/2010","last_update_posted":"2018-08-07"},{"id":"bca8826f-f41b-498f-a758-040745e6d9a6","acronym":"UPCI 13-165","url":"https://clinicaltrials.gov/study/NCT02204020","created_at":"2021-01-18T10:18:05.074Z","updated_at":"2024-07-02T16:37:12.633Z","phase":"Phase 2","brief_title":"Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS","source_id_and_acronym":"NCT02204020 - UPCI 13-165","lead_sponsor":"University of Pittsburgh","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 05/04/2016","study_completion_date":" 05/04/2016","last_update_posted":"2018-03-30"}]